Literature DB >> 21181207

Markers of childhood lupus nephritis indicating disease activity.

Monika Edelbauer1, Sudhir Kshirsagar, Magdalena Riedl, Dieter Haffner, Heiko Billing, Burkhard Tönshoff, Sophia Ross, Jörg Dötsch, Oliver Amon, Henry Fehrenbach, Christian Steuber, Antje Beissert, Josef Hager, Gottfried Wechselberger, Lutz T Weber, Lothar Bernd Zimmerhackl.   

Abstract

Current treatment regimens for childhood lupus nephritis (LN) are associated with significant side-effects and toxicity in vulnerable phases of growth and development. The paucity of biomarkers particularly in childhood impedes the appropriate clinical management and the development of new therapeutics. We analyzed markers of immune system (BAFF, RANTES), complement (Bb, C1q, C3d-CIC, C5a) and endothelial cell activation (sVCAM-1) in children with LN (n=22, mean age 14.8±4.7 years), nephrotic syndrome (n=13) and age-matched healthy controls (n=20) to define parameters that correlate with LN activity. Complement fragments of the alternative (Bb, p=0.0004) classical (C3d-CIC, p<0.0001) and common pathway (C5a, p<0.0001) and the levels of BAFF (p<0.0001), RANTES (p=0.0002) and sVCAM-1 (p=0.0004) were significantly higher in active compared to inactive LN. Activation of complement was associated with the occurrence of anti-C1q antibodies and reduced complement C1q. Complement-activation fragments highly correlated with the markers for immune system and endothelial cell activation. The ensemble of these parameters may be of great value in identifying early flares or remissions of childhood LN, and moreover may prove useful in the assessment of new treatments and in determining the optimization of their use.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21181207     DOI: 10.1007/s00467-010-1720-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  59 in total

Review 1.  Systemic lupus erythematosus, complement deficiency, and apoptosis.

Authors:  M C Pickering; M Botto; P R Taylor; P J Lachmann; M J Walport
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

2.  Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.

Authors:  Xuebing Feng; Hui Wu; Jennifer M Grossman; Punchong Hanvivadhanakul; John D FitzGerald; Grace S Park; Xin Dong; Weiling Chen; Michelle H Kim; Haoling H Weng; Daniel E Furst; Alan Gorn; Maureen McMahon; Mihaela Taylor; Ernest Brahn; Bevra H Hahn; Betty P Tsao
Journal:  Arthritis Rheum       Date:  2006-09

3.  High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis.

Authors:  Marten Trendelenburg; Margarita Lopez-Trascasa; Eliska Potlukova; Solange Moll; Stephan Regenass; Véronique Frémeaux-Bacchi; Jorge Martinez-Ara; Eva Jancova; Mari Luz Picazo; Eva Honsova; Vladimir Tesar; Salima Sadallah; Jürg Schifferli
Journal:  Nephrol Dial Transplant       Date:  2006-07-28       Impact factor: 5.992

4.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

5.  Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage.

Authors:  Hermine I Brunner; Earl D Silverman; Theresa To; Claire Bombardier; Brian M Feldman
Journal:  Arthritis Rheum       Date:  2002-02

6.  Accurately describing changes in disease activity in Systemic Lupus Erythematosus.

Authors:  D D Gladman; M B Urowitz; A Kagal; D Hallett
Journal:  J Rheumatol       Date:  2000-02       Impact factor: 4.666

7.  Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis.

Authors:  Tamar Rubinstein; Milena Pitashny; Benjamin Levine; Noa Schwartz; Julie Schwartzman; Elena Weinstein; Jose M Pego-Reigosa; Tim Y-T Lu; David Isenberg; Anisur Rahman; Chaim Putterman
Journal:  Rheumatology (Oxford)       Date:  2010-02-09       Impact factor: 7.580

8.  C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist.

Authors:  Lihua Bao; Iyabo Osawe; Tipu Puri; John D Lambris; Mark Haas; Richard J Quigg
Journal:  Eur J Immunol       Date:  2005-08       Impact factor: 5.532

9.  Anti-C1q antibodies in juvenile-onset systemic lupus erythematosus.

Authors:  A A Jesus; C A Silva; M Carneiro-Sampaio; M Sheinberg; C L Mangueira; S K Marie; B L Liphaus
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

Review 10.  The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.

Authors:  Michael P Cancro; David P D'Cruz; Munther A Khamashta
Journal:  J Clin Invest       Date:  2009-05-01       Impact factor: 14.808

View more
  9 in total

1.  Molecular mechanisms for synchronized transcription of three complement C1q subunit genes in dendritic cells and macrophages.

Authors:  Guobao Chen; Carol Shurong Tan; Boon King Teh; Jinhua Lu
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

2.  Novel biomarkers for the assessment of paediatric systemic lupus erythematosus nephritis.

Authors:  A Koutsonikoli; M Trachana; E Farmaki; V Tzimouli; P Pratsidou-Gertsi; N Printza; A Garyphallos; V Galanopoulou; F Kanakoudi-Tsakalidou; F Papachristou
Journal:  Clin Exp Immunol       Date:  2017-01-22       Impact factor: 4.330

Review 3.  Advances in biomarkers for paediatric rheumatic diseases.

Authors:  Alessandro Consolaro; Giulia C Varnier; Alberto Martini; Angelo Ravelli
Journal:  Nat Rev Rheumatol       Date:  2014-12-16       Impact factor: 20.543

4.  1,25-dihydroxyvitamin D3 ameliorates lupus nephritis through inhibiting the NF-κB and MAPK signalling pathways in MRL/lpr mice.

Authors:  Xuewei Li; Jie Liu; Yingzhe Zhao; Ning Xu; E Lv; Chunzeng Ci; Xiangling Li
Journal:  BMC Nephrol       Date:  2022-07-08       Impact factor: 2.585

5.  Anti-C1q Antibody is Associated with Renal and Cutaneous Manifestations in Asian Indian Patients with Systemic Lupus Erythematosus.

Authors:  Jayakanthan Kabeerdoss; Nikhil Gupta; Sandhya Pulukool; Hindhumathi Mohan; Gowri Mahasampath; Debashish Danda
Journal:  J Clin Diagn Res       Date:  2017-03-01

6.  A single-cell survey of the human glomerulonephritis.

Authors:  Zhejun Chen; Ting Zhang; Kaiqiong Mao; Xinghua Shao; Yao Xu; Minyan Zhu; Hang Zhou; Qin Wang; Zhenyuan Li; YuanYuan Xie; Xiaodong Yuan; Liang Ying; Ming Zhang; Jiajia Hu; Shan Mou
Journal:  J Cell Mol Med       Date:  2021-03-22       Impact factor: 5.310

7.  Urine ALCAM, PF4 and VCAM-1 Surpass Conventional Metrics in Identifying Nephritis Disease Activity in Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Samar A Soliman; Anam Haque; Kamala Vanarsa; Ting Zhang; Faten Ismail; Kyung Hyun Lee; Claudia Pedroza; Larry A Greenbaum; Sherene Mason; M John Hicks; Scott E Wenderfer; Chandra Mohan
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

8.  The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.

Authors:  Yu Shi; Wen Yao; Li Sun; Guomin Li; Haimei Liu; Peipei Ding; Weiguo Hu; Hong Xu
Journal:  BMC Nephrol       Date:  2019-11-21       Impact factor: 2.388

9.  Urinary activated leukocyte cell adhesion molecule as a novel biomarker of lupus nephritis histology.

Authors:  Huihua Ding; Cheng Lin; Jingyi Cai; Qiang Guo; Min Dai; Chandra Mohan; Nan Shen
Journal:  Arthritis Res Ther       Date:  2020-05-27       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.